- Home
- MLTX vs CERT Comparison
MLTX vs CERT Comparison
Compare MLTX & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MLTX | CERT |
|---|---|---|
| Founded | 2021 | 2008 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 978.7M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MLTX | CERT |
|---|---|---|
| Price | $18.91 | $5.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 10 |
| Target Price | ★ $27.50 | $12.22 |
| AVG Volume (30 Days) | 828.6K | ★ 4.1M |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.50 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $418,838,000.00 |
| Revenue This Year | N/A | $4.26 |
| Revenue Next Year | N/A | $5.40 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.75 |
| 52 Week Low | $5.95 | $5.60 |
| 52 Week High | $62.75 | $15.38 |
Technical Indicators
Market Signals| Indicator | MLTX | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 50.39 | 30.48 |
| Support Level | $16.52 | N/A |
| Resistance Level | $19.03 | $7.52 |
| Average True Range (ATR) | 0.89 | 0.27 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 42.76 | 14.17 |
Price Performance
Historical ComparisonAbout MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.